Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | FLT3 exon 14 ins |
Therapy | MRX-2843 + Venetoclax |
Indication/Tumor Type | acute myeloid leukemia |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FLT3 exon 14 ins | acute myeloid leukemia | sensitive | MRX-2843 + Venetoclax | Preclinical - Patient cell culture | Actionable | In a preclinical study, the combination of MRX-2843 and Venclexta (venetoclax) induced apoptosis in acute myeloid leukemia (AML) cell lines harboring a FLT3-ITD, including cell lines resistant to Cytosar-U (cytarabine), and induced apoptosis and inhibited colony growth in primary AML cells harboring a FLT3-ITD in culture (PMID: 38968731). | 38968731 |
PubMed Id | Reference Title | Details |
---|---|---|
(38968731) | Combining the novel FLT3 and MERTK dual inhibitor MRX-2843 with venetoclax results in promising antileukemic activity against FLT3-ITD AML. | Full reference... |